Abilify

AbilifyHEADER

 

 

 

 

 

 

In 2013, Abilify® was the top selling prescription drug in the United States, generating more than $6.5 billion in sales for manufacturers Bristol-Myers Squibb and Otsuka America Pharmaceuticals. Millions of Americans that suffer from serious psychological conditions such as bipolar disorder and depression believed that Abilify® could help alleviate their symptoms.

Abilify® (aripirazole) was approved by the Food and Drug Administration (FDA) in 2002 to treat symptoms of serious psychological conditions such as schizophrenia, bipolar disorder, depression and Tourette syndrome.

The FDA has warned that compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex have been reported with the use of the antipsychotic drug Abilify®. Unfortunately, these side effects have had an extremely negative impact on the lives of many patients.

Patients taking Abilify® have experienced an increase in dangerous, compulsive and addictive behaviors including:

  • Hypersexuality and greater sexual preoccupation
  • Compulsive gambling
  • Compulsive eating
  • Compulsive shopping
  • Other compulsive behaviors

If you or a loved one suffered dangerous side effects after using Abilify® or any other prescription medication, contact The Yost Legal Group at 1-800-YOST-LAW (967-8529).

FDA Warns That Abilify® is Linked to Severe Psychological Side Effects

In April of 2015, the FDA sent a letter to the manufacturers of Abilify® informing them that their marketing of Abilify® made misleading claims and presentations about the drug. The FDA’s letter stated that Bristol-Myers Squibb and Otsuka America Pharmaceuticals claimed to have a greater degree of certainty about the mechanism of action of Abilify® in humans than is currently known.

Abilify® is a new type of antipsychotic works to counteract the symptoms of psychological disorders by targeting dopamine and serotonin receptors in the brain. Studies conducted by the National Center for Biotechnology Information and the British Journal of Psychiatry found that Abilify® can reduce the brain’s capacity to control impulses and compulsive behaviors.

In many patients, this has resulted in the formation of addictive and compulsive behaviors.

In May of 2016, the FDA issued a Drug Safety Communication reiterating that Abilify® use can lead to severe and dangerous impulse control problems. The FDA advised that uncontrollable urges to gamble, eat, shop or engage in sexual behaviors have been observed to stop once Abilify® use was discontinued or the dose was lowered.

These behaviors can result in severe harm to patients and their families if left untreated.

Call The Yost Legal Group for Help

If you or a loved one experienced compulsive behaviors or suffered any other type of harm while taking Abilify®, call The Yost Legal Group at 1-800-YOST-LAW (967-8529) for a FREE, confidential consultation.

At The Yost Legal Group, we have extensive experience standing up to major pharmaceutical manufacturers on behalf of our clients. The Yost Legal Group is made up of experienced attorneys ready to pursue your possible case with compassion and determination.

When you call, we will investigate every detail of your situation at no cost to you and help provide the answers you seek. At The Yost Legal Group, you will never pay an attorney’s fee up front, and you owe us nothing unless we recover for you.

The Yost Legal Group – Experienced Attorneys Dedicated to Protecting Your Rights